News
Amolyt Pharma Enters into Definitive Agreement to be Acquired by AstraZeneca
Amolyt Pharma, a global, clinical-stage biopharmaceutical company specializing in developing therapeutic peptides for rare endocrine and related diseases, today announced it has entered into a definitive agreement for AstraZeneca to acquire Amolyt Pharma at a purchase...
Inalve raises 2m€ to accelerate the aquaculture transition toward a more sustainable industry
Inalve, a leader in biofilm-based production of microalgae, announces the successful closing of a 2m € financing round The round was l ed by Seventure Partners’ Blue Forward Fund TM ( France). Existing investors including Kreaxi and Angelor also participated ....
Amolyt Pharma Named ‘Biotech Company of the Year” at the LSX European Lifestars Awards
Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, has been awarded ‘Biotech Company of the Year 2023’ at the annual LSX, European Lifestars Awards Ceremony, held on November 13th in London, U.K....
Greentech: MECAWARE secures €40m to become the leader in battery recycling and the production of strategic metals in France and Europe
This funding will enable the industrialisation of the pilot scheme for the recycling of battery production scrap (Gigafactories Scrap - ScrapCO2MET project), which will be operational in 2025. This tool will produce 50 tonnes of recycled metal per year, in particular,...
Amolyt Pharma to Present Data on the Renal Effects of Eneboparatide, a PTHR1 Agonist in Phase 3 for the Treatment of Hypoparathyroidism, at the 39th Congress of the French Society of Endocrinology
Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced that it will present data on eneboparatide, the company’s investigational lead product candidate for the treatment of...
Amolyt Pharma to Host Hybrid Key Opinion Leader Event on Eneboparatide, a PTHR1 Agonist Entering phase 3 for the Treatement of Hypoparathyroidism, in Chicago on June 16, 2023
Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced that it will host an in-person key opinion leader (KOL) event on eneboparatide, the company’s investigational lead product candidate...
Primo1D Teams Up with Decathlon to Bring Garment Tracingto the Recycling Sector Thanks to its E- Thread™ Technology
Primo1D, a world leader in smart embedded Radio Frequency Identification (RFID) tags, today announced a paradigm shift in the way textiles are recycled. By using Primo1D’s RFID E-Thread™ embedded into Decathlon garments, the company reached a major milestone to...
Amolyt Pharma Launches Public Awareness Campaign to Honor World Hypoparathyroidism Awareness Day
Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced its support of World Hypoparathyroidism Awareness Day, which is observed annually on June 1. Complete Press Release Amolyt Pharma
Ciliatech raises €3.5M in Series A funding
Ciliatech, an ophthalmology medtech company developing a new class of implant to treat glaucoma durably, today announces it has raised €3.5M (approx. $4M) from BNP Développement, Kreaxi and Bernard Chauvin, all historical investors. This Series A funding is composed...
Ciliatech reports positive clinical results on novel glaucoma implant, CID, in 24-month post-operative follow-up
Ciliatech, an ophthalmology medtech company developing a new class of implant to treat glaucoma durably, today announces the positive results of a 24-month post-operative follow-up on a clinical trial of CID, its first generation Cilio-scleral Inter-positioning...